The health economic impact of antidepressant usage from a payer's perspective: A multinational study

International Journal of Clinical Practice

Volumn 55, Issue 5, 2001, Pages 292-299

  Casciano, J ^a   Doyle, J ^a   Arikian, S ^b   Casciano, R ^b  

^a Analytica Group   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DEPRESSION; DRUG COST; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; EUROPE; FINANCIAL MANAGEMENT; HEALTH CARE; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN; MARKET; MEDICAL LITERATURE; META ANALYSIS; MODEL; PRIORITY JOURNAL; PUBLICATION; SIDE EFFECT; SYMPTOM; WESTERN HEMISPHERE;

ACUTE DISEASE; ALGORITHMS; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DRUG COSTS; EUROPE; HEALTH CARE COSTS; HEALTH POLICY; HUMANS; NORTH AMERICA;

EID: 0034950553     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Henry JA, Rivas CA. Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: depression and its treatment. Pharmacoeconomics 1997: 11(5): 419-443.
2. Greenberg PE, Stiglin LE, Finkelstein SN. Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54(11): 405-418.
3. Kind P, Sorensen J. The costs of depression. Int Clin Psvchopharmacol 1993; 7(3/4): 191-195.
4. Lepine JP, Gastpar M, Mendlewicz J, Tylee A. Depression in the community: the first pan-European study DEPRES. Int Clin Psvchopharmacol 1997;12(1): 19-29.
5. President and Fellows of Harvard College. How much does depression cost society? Harvard Mental Health Letter 1994.
6. Einarson TR, Arikian SR.Casciano J, Doyle JJ. Comparison of extended release venlafaxine, serotonin reuptake inhibitors and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized clinical trials. Clin Therapeut 1999; 21(2): 296-308.
7. Busse R, Howorth C, Schwanz FW. The future development of the rights based approach to health care in Germany: more rights or fewer. Hard choices in health care 1997; 3: 21-47.
8. Ulrich V, Wille E. Health care reform and expenditures on drugs: the German situation. Pharmacoeconomics 1996; 10(suppl 2): 81-88.
9. Del Vecchio M. Guaranteed entitlement to health care: an Italian point of view. In: Lenaghan J, Ed. Hard choices in health care. London: BMJ Books 1997; 160-175.
10. Mapelli V. Cost-containment measures in the Italian health care system. Pharmacoeconomics 1995; 8(2): 85-89.
11. WHO/Europe. Country profile, 1996.
12. Rovira R. Are national drug expenditure control policies compatible with a single European market? Pharmacoeconomics 1996; 10(suppl 2): 4-13.
13. Cabases JM. Guaranteed health care entitlement in Spain. Hard choices in health care 1997; 4: 48-67.
14. De Marino MA, Marques JM. Velasco A. Impact of selective financing of drugs on pharmaceutical expenditures control in the province of Valladolid, Spain. Pharmacoeconomics 1996; 10(3): 269-280.
15. Caro Research for Wyeth-Ayerst. Swedish health care system. 1997.
16. Jönsson B. Cost-sharing for pharmaceuticals: the Swedish reimbursement system. Pharmacoeconomics 1996; lO(suppl): 267-274.
17. Svensson P-G. Guaranteed entitlement to health care: selected views on Sweden. In: Lenaghan J, Ed. Hard choices in health care. London: BMJ Books, 1997.
18. WHO/Europe. Health care services. Country information, 1996.
19. Lenaghan J. Citizens'rights to health care in the UK: developing a national framework of entitlement. Hard choices in health care 1997; 5: 68-91.
20. Towse A. The UK pharmaceutical market. Pharmacoeconomics 1996; 10(suppl 2): 14-25.
21. Walley T. Drug rationing in the UK National Health Service. Pharmacoeconomics 1997; 12(3): 339-350.
22. Agency for Health Care and Policy Research. Research about managed care. Silver Springs, MD: AHRQ Publications Clearinghouse, 1997.
23. Health Care Financing Administration, www.hcfa.gtn: Managed care in medicare and Medicaid. Fact Sheet. 1997.
24. PAHO (American Health Organisation) www.palw.orfl. Venezuela, Country profile.
25. Einarson TR, Arikian S, Doyle JJ. Rank Order Stability Analysis (ROSA): testing pharmacoeconomic data. Medical Decision Making 1995: 15: 367-372.
26. http://www.who.ch/programmt's/mnh/mnh/ems/rates/iinipo/ar.hlm (WHO online database).
27. Organisation for Economic Cooperation and Developmen www.oecd.org/els/health.htm. Health data. 1997. Paris. France: OECD Health Policy Unit, 1997.
28. Henry JA. Debits and credits in the management of depression. Br J Psychiatry 1993; 163(suppl 20): 33-39.